Previous studies have revealed a significant correlation between Bcl-xL expression and carboplatin-resistance [8]–[10], and increased sensitivity to standard chemotherapeutic agents of ovarian cancer cell lines when Bcl-xL expression is inhibited [11]–[13]. Here, BCL2L1 is linked to ovarian carcinoma.